Clinical Trials Browser

Phase 2 × taletrectinib × 30 days × Clear all

NCT06214793 2026-06-05

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Phase 2 Suspended

Breast Neoplasms